SCY-247

August 10, 2026: SCYNEXIS (NASDAQ: SCYX) reported a corporate update and Q2 2026 results highlighting pipeline catalysts. SCY-770, a first-in-class direct AMPK activator for autosomal dominant polycystic kidney disease (ADPKD), entered Phase 1 on June 30, 2026. The study is evaluating food effect and pharmacokinetics of two dosing regimens to support dose selection for a planned Phase 2 ADPKD trial. Topline Phase 1 data are expected in Q3 2026; the Phase 2 proof-of-concept study remains on track to start in Q4 2026, with an early efficacy readout expected in 2H 2027. The company also said SCY-770 has FDA Orphan Drug Designation for ADPKD.

SCY-247, a second-generation antifungal, completed dosing in the Phase 1 study of its IV formulation, with topline data also expected in Q3 2026.

For ibrexafungerp/BREXAFEMME, SCYNEXIS said it believes GSK is committed to a relaunch; after relaunch, SCYNEXIS could receive up to about $146 million in annual net sales milestones plus low- to mid-single-digit royalties.

Cash, cash equivalents, and investments were $71.1 million as of June 30, 2026, which the company said supports operations into 2029.